[HTML][HTML] Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
B Kaufman, R Shapira-Frommer… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
B Kaufman, R Shapira-Frommer, RK Schmutzler, MW Audeh, M Friedlander, J Balmaña…
Journal of clinical oncology, 2015•ncbi.nlm.nih.govOlaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2
Mutation - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI
Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol
PMC6057749 Other Formats PubReader PDF (178K) Actions Cite Collections Share
Permalink Copy RESOURCES Similar articles Cited by other articles Links to NCBI …
Mutation - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI
Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol
PMC6057749 Other Formats PubReader PDF (178K) Actions Cite Collections Share
Permalink Copy RESOURCES Similar articles Cited by other articles Links to NCBI …
Abstract
Purpose
Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2)–associated breast and ovarian cancers. We evaluated the efficacy and safety of olaparib in a spectrum of BRCA1/2-associated cancers.
ncbi.nlm.nih.gov